06 Dec 2012 Posted in Opinion By Stephen Whitehead
To be clear, we believe that access to trial data is in the best interests of patients and medicines, and that study findings need to be communicated, whatever the outcome, for the benefit of the community at large. Some of the issues and examples highlighted in Dr Goldacre’s book Bad Pharma are clearly historical and have been addressed by the companies involved. However, we have always recognised that there is still a great deal more work to be done in this area.
The pharmaceutical industry has been and continues to be committed to addressing the issues in reporting clinical trial data. The ABPI is actively involved in playing a meaningful role in the discussion. However, clinical research is a truly global process and, in this context, the ABPI is working at European and International levels, and in partnership with all relevant stakeholders. You can read our full position here.